Abstract
Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Here we report the case of a 74-year-old woman with psoriasis vulgaris and psoriatic arthritis complicated by breast cancer after systemic treatments including etretinate, cyclosporine, methotrexate, adalimumab, and ustekinumab.
| Original language | English |
|---|---|
| Pages (from-to) | 185-187 |
| Number of pages | 3 |
| Journal | Acta medica Okayama |
| Volume | 72 |
| Issue number | 2 |
| Publication status | Published - 2018 |
Keywords
- Biologics
- Malignancy
- Psoriasis
- Systemic therapy
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
